N,N-二乙基-4-氨甲基苯甲酸甲酯 | 68453-55-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N,N-二乙基-4-氨甲基苯甲酸甲酯
• 英文名称: methyl 4-((diethylamino)methyl)benzoate
• 英文别名: methyl 4-[(diethylamino)methyl]benzoate；methyl 4-(diethylaminomethyl)-benzoate；4-Diethylaminomethyl-benzoic acid methyl ester；methyl 4-(diethylaminomethyl)benzoate
• CAS: 68453-55-4
• 化学式: C₁₃H₁₉NO₂
• mdl: MFCD11175864
• 分子量: 221.299
• InChiKey: WDNJENVQGOKGDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-二乙基-4-氨甲基苯甲酸甲酯 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 4.0h， 生成 4-乙氨基甲基苯甲酸
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

  摘要：

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.001
• 作为产物：
  描述：

  4-(二乙基氨基甲酰)苯甲酸甲酯 在 三(三苯基膦)羰基氢化铑 二苯基硅烷 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 以70%的产率得到N,N-二乙基-4-氨甲基苯甲酸甲酯
  参考文献：
  名称：

  铑配合物通过催化氢化硅烷化将酰胺还原为胺

  摘要：

  在室温下，通过0.1摩尔％的RhH（CO）（PPh 3）3促进使用2摩尔当量的二苯基硅烷还原各种叔酰胺，从而以高收率提供相应的叔胺。通过化学选择性还原具有官能团如酯和环氧基团的酰胺的化学选择还原证明了常规的用LiAlH 4和BH 3的还原不能耐受的酰胺。

  DOI：

  10.1016/s0040-4039(97)10804-8

文献信息

• Triazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06265426B1

  公开（公告）日：2001-07-24

  The present invention relates to triazole and imidazole derivatives of formula I and to their pharmaceutically acceptable acid addition salts. These compounds are NMDA receptor subtype blockers and are useful for the treatment of diseases related to the NMDA receptor.

  本发明涉及式I的三唑和咪唑衍生物及其药用可接受的酸盐。这些化合物是NMDA受体亚型阻滞剂，对治疗与NMDA受体相关的疾病有用。
• Lewis Acid-Catalyzed Reductive Amination of Carbonyl Compounds with Aminohydrosilanes
  作者：Katsukiyo Miura、Kazunori Ootsuka、Shuntaro Suda、Hisashi Nishikori、Akira Hosomi

  DOI：10.1055/s-2001-17486

  日期：——

  The TiCl4-catalyzed reaction of aromatic carbonyl compounds with (dialkylamino)dimethylsilanes gave tertiary amines in moderate to high yields. The reductive amination of aliphatic aldehydes was effectively catalyzed by ZnI2. Methyl N-(dimethylsilyl)carbamate as well could be used for reductive amination of carbonyl compounds in the presence of Ph3CClO4.

  四氯化钛催化的芳香醛与(二烷基氨基)二甲基硅烷反应，能以中等至高产率得到叔胺。脂肪醛的还原胺化反应也受到ZnI2的有效催化。在存在Ph3CClO4的情况下，甲基N-(二甲基硅基)氨基甲酸酯同样可用于羰基化合物的还原胺化。
• Pyrazolopyrimidine compound and a process for preparing the same
  申请人：Takamuro Iwao

  公开号：US20060135525A1

  公开（公告）日：2006-06-22

  The present invention provides a novel pyrazolopyrimidine compound of the formula [I]: wherein R′ is (A) a substituted aryl group, (B) an optionally substituted nitrogen-containing aliphatic heteromonocyclic group, (C) a substituted cyclo-lower alkyl group, (D) an optionally substituted amino group, or (E) a substituted heteroaryl group, R 2 is (a) an optionally substituted heteroaryl group or (b) an optionally substituted aryl group, Y is a single bond, a lower alkylene group or a lower alkenylene group, Z is a group of the formula: —CO—, —CH2-, S02- or a group of the formula [II]: Q is a lower alkylene group, and q is an integer of 0 or 1 or a pharmaceutically acceptable sait thereof, which has a small conductance potassium channel (SK channel) blocking activity and is useful as a medicament and a process for preparing the same.

  本发明提供了一种新型的吡唑嘧啶化合物，其化学式为[I]：其中R′为（A）取代芳基，（B）可选取代的含氮脂肪杂环基，（C）取代的环低烷基，（D）可选取代的氨基或（E）取代的杂环芳基；R2为（a）可选取代的杂环芳基或（b）可选取代的芳基；Y为单键，低碳基烷基或低碳基烯基；Z为式[II]的基团：其中Q为低碳基烷基，q为0或1的整数，或其药学上可接受的盐。该化合物具有小电导钾通道（SK通道）阻滞活性，并可作为药物使用，以及其制备方法。
• HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：Kozikowski Alan

  公开号：US20140128408A1

  公开（公告）日：2014-05-08

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.

  本发明公开了组蛋白去乙酰化酶抑制剂（HDACIs）及其组成物。公开了治疗疾病和状况的方法，其中抑制HDAC提供了益处，如癌症、神经退行性疾病、周围神经病变、神经疾病、创伤性脑损伤、中风、高血压、疟疾、自身免疫疾病、自闭症、自闭症谱系障碍和炎症。
• Triazole and imidazole derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1070708A1

  公开（公告）日：2001-01-24

  The present invention relates to compounds of the general formula wherein R1 ― R4signify independently hydrogen, -CF3, -OCF3, OCHF2, -OCH2F, lower alkyl, lower alkoxy, halogen, hydroxy, phenyl, benzyl, amino, nitro, pyrrol-1-yl, lower alkyl-sulfonyl, lower alkyl-sulfanyl, cyano or benzyloxy; or R2 and R3may be together ―O-(CH2)2-O-, -O-CH2-O-, -O-(CH2)2-, -(CH2)3- or ―CH=CH-CH=CH-; Xsignifies ―N=, -N(R8)- or ―CH=; Ysignifies ―N=, =N-, -N(R8)- or ―CH=; wherein one of X or Y has to be nitrogen; R5signifies the group wherein R6 and R7signify independently from each other hydrogen, lower alkyl, -C(O)-lower alkyl, hydroxy-lower alkyl, lower alkenyl, -C(O)CH2OH or R6 and R7may be together with the N-atom ―(CH2)n-, -(CH2)2-O-(CH2)2-, -CH2-CH=CH-CH2, -CH2-CH[OC(O)CH3]-(CH2)2, -CH2-CH[NHC(O)CH3]-(CH2)2, -O-(CH2)3-, -CH2-CH(OCH3)-(CH2)2-, -CH2-CH(halogen)-(CH2)2-, -(CH2)2-CH(O-phenyl)-(CH2)2-, -(CH2)2-N(CHO)-(CH2)2-, -(CH2)2-N(COCH3)-(CH2)2-, -CH2-CH(OH)-(CH2)3-, -(CH2)2-CH(OH)-(CH2)2- or -(CH2)2-N(benzyl)-CH2)2-; nsignifies 3 to 5; and R8signifies hydrogen, lower alkyl, lower alkenyl, lower alkinyl, -(CH2)m-O-lower alkyl, -(CH2)m-OH, -(CH2)m-CHF2, -(CH2)m-CH2F, -(CH2)m-C(O)-lower alkyl, - (CH2)m-C(O)O-lower alkyl, -(CH2)m-CH(OH)-lower alkyl, -(CH2)m-CH(OH)-(CH2)mOH, -(CH2)m-C6H5, which phenyl ring is optionally substituted by lower alkyl, lower alkoxy or hydroxy, -(CH2)m-C(=CH2)-lower alkyl, - (CH2)m-cycloalkyl, -(CH2)m-CN, -(CH2)m-pyridin-4-yl, -(CH2)m-pyridin-3-yl or - (CH2)m-pyridin-2-yl; msignifies 0 to 4; and to their pharmaceutically acceptable acid addition salts. These compounds may be used for the treatment of diseases related to the NMDA receptor subtype selective blockers.

  本发明涉及通式如下的化合物 式中 R1-R4独立地表示氢、-CF3、-OCF3、OCHF2、-OCH2F、低级烷基、低级烷氧基、卤素、羟基、苯基、苄基、氨基、硝基、吡咯-1-基、低级烷基磺酰基、低级烷基硫酰基、氰基或苄氧基；或 R2 和 R3 可以是-O-(CH2)2-O-、-O-CH2-O-、-O-(CH2)2-、-(CH2)3- 或-CH=CH-CH=CH-； X表示-N=、-N(R8)-或-CH=； Y表示-N=、=N-、-N(R8)-或-CH=；其中 X 或 Y 必须有一个是氮； R5 表示基团 其中 R6 和 R7 互不独立地表示氢、低级烷基、-C(O)-低级烷基、羟基-低级烷基、低级烯基、-C(O)CH2OH 或 R6 和 R7 可与 N 原子一起为-(CH2)n-、-(CH2)2-O-(CH2)2-、-CH2-CH=CH-CH2、-CH2-CH[OC(O)CH3]-(CH2)2、-CH2-CH[NHC(O)CH3]-(CH2)2、-O-(CH2)3-、-CH2-CH(OCH3)-(CH2)2-、-(CH2)2-N(CHO)-(CH2)2-，-(CH2)2-N(COCH3)-(CH2)2-，-CH2-CH(OH)-(CH2)3-，-(CH2)2-CH(OH)-(CH2)2-或-(CH2)2-N(苄基)-CH2)2-； 表示 3 至 5；以及 R8表示氢、低级烷基、低级烯基、低级炔基、-(CH2)m-O-低级烷基、-(CH2)m-OH、-(CH2)m-CHF2、-(CH2)m-CH2F、-(CH2)m-C(O)-低级烷基、-(CH2)m-C(O)O-低级烷基、-(CH2)m-CH(OH)-低级烷基、-(CH2)m-CH(OH)-低级烷基、-(CH2)m-CH(OH)-(CH2)m-mOH-(CH2)m-C6H5，其中苯基环任选被低级烷基、低级烷氧基或羟基、-(CH2)m-C(=CH2)-低级烷基、-(CH2)m-环烷基、-(CH2)m-CN、-(CH2)m-吡啶-4-基、-(CH2)m-吡啶-3-基或-(CH2)m-吡啶-2-基取代； 表示 0 至 4； 及其药学上可接受的酸加成盐。这些化合物可用于治疗与 NMDA 受体亚型选择性阻断剂有关的疾病。